Uniogen Oy. Health technology company Uniogen is developing next-generation diagnostic solutions for the detection of cancers and infectious diseases. The company aims to revolutionize early-stage cancer diagnostics by introducing a simple and accurate blood test to the market.
If Uniogen’s developed method were utilized globally in the diagnosis of ovarian cancer, an estimated 80,000 lives could be saved annually. The company also holds patents related to colorectal, bladder, breast, prostate, and pancreatic cancer determinations, among others.
Uniogen’s strength lies in its multidisciplinary expertise, which was formed through the merger of three companies that had successfully operated in their respective specialized areas for over 10 years. The company currently employs approximately 100 experts in the field of diagnostics and multidisciplinary professionals in health technology.
Uniogen conducted a 2.8 million euro share issue in March 2024 with Springvest as organizer, attracting 500 investors. Biggest shareholders Arctic Partners.
Investment in 2024.